In our lung cancer quiz, you’ll get to test your knowledge on the ALEX study.
What is the ALEX study?
a. A comparison of alectinib (Alecensa) versus crizotinib (Xalkori) in treatment-naïve ALK-positive non-small cell lung cancer (NSCLC)
b. An evaluation of sotorasib in patients with KRAS G12C-mutant advanced NSCLC
c. A comparison of nivolumab (Opdivo) plus chemotherapy versus chemotherapy alone in patients with resectable NSCLC
d. A comparison of cemiplimab-rwlc (Libtayo) monotherapy in patients with advanced NSCLC with PD-L1 expression on at least 50% of their tumor cells